Atea Pharmaceuticals, Inc. (AVIR)☆SHARE ON XDOWNLOAD PNGHealthcare$5.51+1.47%CloseBUYRECOVERY · day 52AVIR▲ BUY$5.51+1.47%☆OverviewFinancialsFinEarningsEarnAnalyst & RatingsAnalystNewsHolders & ETFsHoldOptionsKey statsMarket cap$441MAvg volume333.0KPrediction marketsKalshi · Polymarket · … linkedFull prediction markets →Loading markets…Company newsseekingalpha.com · 12d agoAtea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcriptmarketbeat.com · 13d agoAtea Pharmaceuticals Q2 Earnings Call Highlightsglobenewswire.com · 13d agoAtea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com · 20d agoAtea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026globenewswire.com · 28d agoAtea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virusglobenewswire.com · 42d agoAtea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virusglobenewswire.com · 61d agoAtea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Viruszacks.com · 68d agoAtea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Knowzacks.com · 77d agoAre Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?seekingalpha.com · 88d agoAtea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalystglobenewswire.com · 90d agoAtea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026Market news & ticker search · RSS for AVIR
